Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Closure

IND.182 -- A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma -- was closed 24 March 2009.
http://www.ctg.queensu.ca/trials/ind/i182/182.html